Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Monoclonal Antibody Therapeutics Market: By Source Type By Application, By End User and Region Forecast 2020-2031
Monoclonal Antibody Therapeutics Market size was valued at US$ 254.88 billion in 2024 and is expected to reach US$ 657.61 billion by 2031, growing at a significant CAGR of 14.5% from 2025-2031. The monoclonal antibody therapeutics industry seeks to develop and sell monoclonal antibodies (mAbs) as therapeutic agents against diseases, including cancer, autoimmune disorders, and infectious diseases. The market is driven by technological advancements in biotechnology, increasing incidence of chronic diseases, and drug development investments, enabling highly targeted treatments with greater efficacy. Restrictions to market expansion are high development expenses, rigorous regulatory approval, and biosimilar competition for established products. Though these limitations cause the market to retreat, developments in manufacturing technologies and expanding usage of personalized medicine will result in further growth in the market.
Based on the source type:
The human source type dominated the largest proportion. Human mAbs provide effective modulation in effector functions and are less immunogenic than chimeric or humanized mAbs. These kinds of antibodies may be generated by application of phage display and hybridoma technologies to transgenic mice. Consequently, owing to recent technological advancements in genetic engineering, the manufacture of fully human mAbs is expected to gain momentum in the near future.
Based on the application:
Oncology segment accounted for the highest share in the applications market for mAbs. This is due to the fact that a high rate of regulatory approvals for the treatment of cancer using mAbs has occurred. Cancer prevalence is one of the major drivers that are expected to drive mAbs therapeutics growth since they may have zero or minimal side effects as compared to other drugs and chemotherapy. Some of the mAb therapies used now are non-small cell lung, brain tumor, ovarian, breast, gastric, melanoma, colorectal, Hodgkin's lymphoma, etc.
Based on the end user:
The hospitals segment accounted for the maximum market share because of the rising use of mAbs in cancer treatment at hospitals. Increased healthcare spending worldwide, patient awareness levels rising, and ready availability of sophisticated hospital infrastructure in developed nations are the drivers set to lead the segment to hold dominance in the forecast period.
Study Period
2025-2031Base Year
2024CAGR
14.5%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Genetic engineering technology and biotechnology are driving market expansion for monoclonal antibody therapeutics by enabling the creation of extremely targeted drugs with greater effectiveness. Increasing rates of chronic conditions such as cancer, autoimmune diseases, and infectious diseases are driving demand for monoclonal antibody therapy. Support from government authorities and expedited approval procedures are propelling market growth by putting new treatments into the hands of patients sooner. In addition to that, enormous R&D investments are expanding monoclonal antibody therapeutic applications and further promoting the market.
Monoclonal antibody treatments market is faced with several limitations, including expensive treatment and production costs, that limit access, particularly in poor nations. Strict regulatory controls and lengthy delay times in approvals stifle innovation and market access. Biosimilar entry brings competitive pressure, which could influence prices and market share for established monoclonal antibody treatments. Additionally, manufacturing complexities in mass scale and supply chain could limit availability and affordability.
The market offers numerous opportunities for development and expansion. Development is becoming more efficient, lowering the cost and speeding up clinical trials, with increasing growth in the use of AI-based drug discovery, which is improving the efficiency of monoclonal antibody development. Bispecific and multispecific antibody development is widening the number of therapeutic applications, especially in oncology and autoimmune diseases. Asia-Pacific and Latin American emerging economies are highly profitable with greater investment in healthcare and greater accessibility of biologic drugs. Increased focus on targeted therapies through monoclonal antibodies is fueling the market for improved and targeted therapy. Increased opportunities through biosimilars are also making space for cheap alternatives, hence making them easily available to patients across the globe.
Monoclonal antibody drug market is transforming with a few major trends shaping its evolution. Fusion of drug discovery with AI is accelerating monoclonal antibody R&D, making it more effective and economical. Bispecific and multispecific antibody technologies are expanding therapeutic use spaces, primarily in cancer and autoimmune diseases. Rise in biosimilars is fueling competition and spurring access to affordable therapies. Targeted treatment with monoclonal antibodies is being driven by personalized medicine, which allows for targeted and more effective treatment. Besides this, the developing markets of the Asia-Pacific nations are driven by rising health care expenditures and growing access to biologic drugs.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 254.88 billion |
Market Size in 2031 |
US$ 657.61 billion |
Market CAGR |
14.5% |
By Source Type |
|
By Application |
|
By End User |
|
By Region |
|
According to PBI Analyst, monoclonal antibody drugs are continuing to make their swift growth, driven by technological innovation in biotechnology, increasing prevalence of chronic disease, and increased spending on drug development. Oncology remains the single most important area of application, with monoclonal antibodies being used widely to treat cancer, including checkpoint inhibitors against PD-1 and PD-L1. The industry is also expanding very strongly in applications involving autoimmune and infectious diseases. Biosimilar adoption is transforming market dynamics, with biosimilar adoption and enhancing access and affordability.
An aging population is fueling market growth, with more than 24 percent of the U.S. population being above 65 years in 2060. In addition, markets such as Asia-Pacific and Latin America are calling out to investments with growing healthcare expenditures and enhanced access to biologic medicines.
Download Free Sample Report
The monoclonal antibody therapeutics market size was valued at US$ 254.88 billion in 2024 and is projected to grow at a CAGR of 14.5% from 2025-2031
Biosimilars are increasing competition, improving affordability, and expanding patient access to monoclonal antibody therapies, reshaping the market landscape.
Asia-Pacific and Latin America are attracting investments due to rising healthcare expenditures, increasing disease prevalence, and improved access to biologic therapies.
High production costs, complex supply chains, and stringent regulatory requirements pose challenges in scaling monoclonal antibody manufacturing.
Monoclonal antibodies offer higher specificity and reduced off-target effects compared to small-molecule drugs, making them ideal for precision medicine applications.
AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Takeda Pharmaceuticals
1.Executive Summary |
2.Global Monoclonal Antibody Therapeutics Market Introduction |
2.1.Global Monoclonal Antibody Therapeutics Market - Taxonomy |
2.2.Global Monoclonal Antibody Therapeutics Market - Definitions |
2.2.1.Source Type |
2.2.2.Application |
2.2.3.End User |
2.2.4.Region |
3.Global Monoclonal Antibody Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Monoclonal Antibody Therapeutics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Monoclonal Antibody Therapeutics Market By Source Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Murine |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Chimeric |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Humanized |
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Human |
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Monoclonal Antibody Therapeutics Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. Oncology |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Autoimmune Diseases |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Infectious Diseases |
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Neurological Diseases |
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Others |
6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7.Global Monoclonal Antibody Therapeutics Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Specialty Centers |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Monoclonal Antibody Therapeutics Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. Source Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Murine |
9.1.2.Chimeric |
9.1.3.Humanized |
9.1.4.Human |
9.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oncology |
9.2.2.Autoimmune Diseases |
9.2.3.Infectious Diseases |
9.2.4.Neurological Diseases |
9.2.5.Others |
9.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Specialty Centers |
9.3.3.Others |
9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Source Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Murine |
10.1.2.Chimeric |
10.1.3.Humanized |
10.1.4.Human |
10.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oncology |
10.2.2.Autoimmune Diseases |
10.2.3.Infectious Diseases |
10.2.4.Neurological Diseases |
10.2.5.Others |
10.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Specialty Centers |
10.3.3.Others |
10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Source Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Murine |
11.1.2.Chimeric |
11.1.3.Humanized |
11.1.4.Human |
11.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oncology |
11.2.2.Autoimmune Diseases |
11.2.3.Infectious Diseases |
11.2.4.Neurological Diseases |
11.2.5.Others |
11.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Specialty Centers |
11.3.3.Others |
11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Source Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Murine |
12.1.2.Chimeric |
12.1.3.Humanized |
12.1.4.Human |
12.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oncology |
12.2.2.Autoimmune Diseases |
12.2.3.Infectious Diseases |
12.2.4.Neurological Diseases |
12.2.5.Others |
12.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Specialty Centers |
12.3.3.Others |
12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Monoclonal Antibody Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Source Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Murine |
13.1.2.Chimeric |
13.1.3.Humanized |
13.1.4.Human |
13.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oncology |
13.2.2.Autoimmune Diseases |
13.2.3.Infectious Diseases |
13.2.4.Neurological Diseases |
13.2.5.Others |
13.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Specialty Centers |
13.3.3.Others |
13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.AbbVie |
14.2.2.Amgen |
14.2.3.AstraZeneca |
14.2.4.Bristol-Myers Squibb |
14.2.5.Eli Lilly |
14.2.6.Genentech |
14.2.7.GlaxoSmithKline |
14.2.8.Johnson & Johnson |
14.2.9.Merck & Co. |
14.2.10.Novartis |
14.2.11.Pfizer |
14.2.12.Regeneron Pharmaceuticals |
14.2.13.Roche |
14.2.14.Sanofi |
14.2.15.Takeda Pharmaceuticals |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players